Skip to Main Content

Paper Details

FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
Cell Death Dis
3
2015
FV-162, ONX-, chymotrypsin-like proteasome, epoxyketone, fluorine, human, human myeloma cell lines, mice, multiple myeloma, murine red blood cells, myeloma, myeloma xenograft model, primary myeloma cells, tripeptide epoxyketone, tumor
Author NameAffiliation
Zhihua LiPrincess Margaret Cancer Centre
Rose HurrenPrincess Margaret Cancer Centre
Ahmed AmanOntario Institute for Cancer Research
Rima Al-AwarOntario Institute for Cancer Research
Lewis E KayUniversity of Toronto
Suzanne TrudelPrincess Margaret Cancer Centre
Suzanne TrudelPrincess Margaret Cancer Centre
Aaron D SchimmerPrincess Margaret Cancer Centre
  • 1 - 8

Datasets

Release 1.2